Mirum Pharmaceuticals (MIRM) Income from Continuing Operations (2019 - 2026)
Mirum Pharmaceuticals (MIRM) recorded quarterly Income from Continuing Operations of 790155000.0 in Q1 2026, down 13689.79% quarter-over-quarter from 5730000.0 in Q4 2025, and down 5283.63% on a YoY basis from 15243282.98 in Q1 2025.
Mirum Pharmaceuticals (MIRM) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Mirum Pharmaceuticals' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 790155000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 5283.63% year-over-year to 790155000.0; the TTM figure through Mar 2026 stood at 798841000.0 (down 932.9% YoY), while the FY2025 annual figure was 23363000.0, up 73.43% from the prior year.
- Income from Continuing Operations was 790155000.0 for Q1 2026 at Mirum Pharmaceuticals, down from 5730000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2905000.0 in Q3 2025 to a low of 790155000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 70620000.0 across 5 years, with a median of 25279000.0 in 2024.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations jumped 120.41% in 2025, then sank 5283.63% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 36431000.0 in 2022, then increased by 2.12% to 35659000.0 in 2023, then surged by 33.28% to 23790000.0 in 2024, then soared by 75.91% to 5730000.0 in 2025, then plunged by 13689.79% to 790155000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 790155000.0 (Q1 2026), 5730000.0 (Q4 2025), and 2905000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Mirum Pharmaceuticals | 6.29 Bn | 5.90 Bn | 131.08 Mn | -790.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -790.16 Mn |
| Dec 31, 2025 | -5.73 Mn |
| Sep 30, 2025 | 2.91 Mn |
| Jun 30, 2025 | -5.86 Mn |
| Mar 31, 2025 | -14.68 Mn |
| Dec 31, 2024 | -23.79 Mn |
| Sep 30, 2024 | -14.24 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -25.28 Mn |
| Dec 31, 2023 | -35.66 Mn |
| Sep 30, 2023 | -23.59 Mn |
| Jun 30, 2023 | -74.04 Mn |
| Mar 31, 2023 | -30.13 Mn |
| Dec 31, 2022 | -36.43 Mn |
| Sep 30, 2022 | -35.71 Mn |
| Jun 30, 2022 | -26.92 Mn |
| Mar 31, 2022 | -36.61 Mn |
| Dec 31, 2021 | 57.55 Mn |
| Sep 30, 2021 | -47.11 Mn |
| Jun 30, 2021 | -43.89 Mn |